NEW YORK--(BUSINESS WIRE)--Sept. 18, 2006--Daxor Corporation (AMEX:DXR), a medical instrumentation and biotechnology company, today announced significant results from blood volume data utilizing Daxor's BVA-100 was reported at the Heart Failure Society of America's (HFSA) Annual Scientific Meeting held last week in Seattle, WA. The studies were reported by physicians from Columbia Presbyterian's College of Physicians and Surgeons.
